A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients

Trial Profile

A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs AZD-1775 (Primary) ; Docetaxel; Pegfilgrastim
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Oct 2016 Results from lead-in portions of this and other study (n=46) presented at the 41st European Society for Medical Oncology Congress.
    • 06 May 2016 Status changed from completed to discontinued.
    • 10 Jun 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top